SGMT Sagimet Biosciences Inc
Price (delayed)
$2.08
Market cap
$66.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.45
Enterprise value
-$8.8M
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid,
Highlights
The EPS has increased by 45% YoY
The quick ratio has surged by 102% year-on-year but it has declined by 9% since the previous quarter
The equity has soared by 71% year-on-year but it has declined by 9% since the previous quarter
The company's revenue has shrunk by 100% YoY
Sagimet Biosciences's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of SGMT
Market
Valuations
Earnings
Shares outstanding
32.2M
Market cap
$66.97M
Enterprise value
-$8.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.43
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$54.45M
Net income
-$45.57M
EBIT
-$45.57M
EBITDA
-$45.42M
Free cash flow
-$42.44M
Per share
Balance sheet
Liquidity
EPS
-$1.45
EPS diluted
-$1.45
Free cash flow per share
-$1.35
Book value per share
$4.84
Revenue per share
$0
TBVPS
$5.11
Total assets
$160.26M
Total liabilities
$4.45M
Debt
$78,000
Equity
$155.81M
Working capital
$148.32M
Debt to equity
0
Current ratio
34.3
Quick ratio
33.96
Net debt/EBITDA
1.67
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-25.4%
Return on equity
-26%
Return on invested capital
-66.4%
Return on capital employed
-29.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SGMT stock price
How has the Sagimet Biosciences stock price performed over time
Intraday
-8.37%
1 week
-43.94%
1 month
-40.57%
1 year
-61.83%
YTD
-53.78%
QTD
-36.2%
Financial performance
How have Sagimet Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$54.45M
Net income
-$45.57M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
Sagimet Biosciences's gross profit has shrunk by 100% YoY
SGMT's operating income has shrunk by 77% YoY and by 19% QoQ
The net income has dropped by 63% year-on-year and by 21% since the previous quarter
Growth
What is Sagimet Biosciences's growth rate over time
Valuation
What is Sagimet Biosciences stock price valuation
P/E
N/A
P/B
0.43
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 45% YoY
The equity has soared by 71% year-on-year but it has declined by 9% since the previous quarter
SGMT's price to book (P/B) is 39% lower than its last 4 quarters average of 0.7
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Sagimet Biosciences business performance
The return on invested capital has surged by 88% year-on-year and by 7% since the previous quarter
Sagimet Biosciences's return on assets has increased by 43% YoY but it has decreased by 11% QoQ
The company's return on equity fell by 10% QoQ
Dividends
What is SGMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SGMT.
Financial health
How did Sagimet Biosciences financials performed over time
The quick ratio has surged by 102% year-on-year but it has declined by 9% since the previous quarter
Sagimet Biosciences's current ratio has surged by 101% YoY but it has decreased by 11% QoQ
The debt is 100% less than the equity
The equity has soared by 71% year-on-year but it has declined by 9% since the previous quarter
The debt has contracted by 33% from the previous quarter but it has grown by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.